Two deaths reported to the FDA have raised concerns about products sold as “Reta.” Here’s what patients should understand about the reports, the science, and medication safety.

Quick Answer

An October 2026 CBS News investigation revealed that the FDA received reports of two deaths involving people who reportedly used products marketed as retatrutide, sometimes called “Reta.”

These reports do not establish that retatrutide caused either death. The FDA has not publicly verified the case details, and the identity and contents of the products involved have not been independently confirmed.

Retatrutide is a promising investigational weight-loss medication that activates three hormone pathways: GLP-1, GIP, and glucagon. However, retatrutide is not FDA-approved, and the FDA states that it cannot legally be sold by others such as Peptide Companies.

The most important distinction is between an investigational medication studied under controlled clinical conditions and products sold through unauthorized channels without the same safeguards.

Two Reported Deaths—and an Important Medical Distinction

On October 13, 2026, CBS News published an investigation describing two deaths reported to the FDA following the use of products represented as retatrutide.

According to the first report, a 41-year-old woman with obesity experienced a dangerously fast heartbeat and cardiac arrest in July. The reporting healthcare professional identified retatrutide as a suspected product and described its source as unreliable.

The second report, submitted in September, described a 49-year-old patient who reportedly purchased retatrutide through an online peptide vendor after receiving guidance from a licensed nurse. The report described severe dehydration, malnutrition, and cardiac arrest.

These are serious and concerning reports, and the individuals and families involved deserve sensitivity and respect.

But there’s an essential distinction I want patients to understand:

A death reported after exposure to a medication is not the same as a death proven to have been caused by that medication.

CBS could not independently verify the information in either report, and the FDA declined to confirm whether the details were accurate. Neither case was connected to an authorized retatrutide clinical trial.

We do not have enough verified information to determine whether the products contained genuine retatrutide, whether other substances or medical conditions contributed, or whether the products caused the deaths.

That uncertainty is not a reason to ignore the reports. It is a reason to examine the safety of unauthorized medications more carefully.

Why Is Retatrutide Generating So Much Interest?

Over the past several years, medications such as semaglutide and tirzepatide have changed how physicians treat obesity.

We now understand that weight regulation involves far more than calories and willpower. The brain, digestive system, pancreas, liver, muscles, and fat tissue communicate through hormones that influence hunger, fullness, blood sugar, and energy balance.

Retatrutide is designed to act on three of those hormonal pathways:

• GLP-1: Helps regulate appetite, fullness, and glucose-dependent insulin release.
• GIP: Influences insulin signaling and metabolic regulation.
• Glucagon: Helps regulate glucose production and energy metabolism.

Semaglutide primarily targets GLP-1. Tirzepatide targets GLP-1 and GIP. Retatrutide adds glucagon receptor activity, making it a triple agonist.

Think of your metabolism as an orchestra. Each hormone plays a different instrument, but the overall result depends on how those signals work together.

Researchers are investigating whether targeting all three pathways can produce greater improvements in body weight and metabolic health.

And the clinical results have been impressive.

What Did the September 2026 Clinical Trial Show?

On September 29, 2026, the New England Journal of Medicine published the Phase 3 TRIUMPH-1 study, titled Retatrutide, a Triple Hormone Receptor Agonist, for Treatment of Obesity.

This randomized, double-blind trial studied once-weekly retatrutide in adults with obesity who did not have diabetes.

At 80 weeks, participants receiving the highest studied dose, 12 mg, experienced an average body-weight reduction of approximately 28.3%.

For someone starting at 250 pounds, that percentage would represent approximately 71 pounds of weight loss, although individual responses vary.

These findings are remarkable for medical obesity treatment.

But we need to understand what they actually demonstrate.

The trial involved a defined investigational medication, controlled dosing, clinical oversight, and systematic safety monitoring. Participants were evaluated under a research protocol.

These results cannot be applied automatically to vials advertised online as “Reta.”

The published clinical trial supports the potential effectiveness of investigational retatrutide. It does not establish the identity, purity, safety, or effectiveness of unauthorized products marketed under that name.

Why Buying “Reta” Online Is Different From Participating in a Clinical Trial

Imagine receiving a prescription for an injectable medication, but nobody can reliably confirm what’s inside the vial.

Is it the correct ingredient?

Is the concentration accurate?

Was it manufactured under appropriate quality controls?

Was it stored properly?

Could it contain contaminants?

Even if the medication itself has therapeutic potential, uncertainty about the product introduces an entirely different safety concern.

Some unauthorized products may contain too much or too little active ingredient, an unexpected substance, or contaminants. That does not mean every product has these defects. It means patients cannot assume pharmaceutical quality without reliable verification.

A label is not proof of what’s inside.

And labeling something “research use only” does not make it appropriate for human injection.

In the CBS investigation, Eli Lilly stated that it had identified suspect products containing incorrect amounts of active ingredients, different ingredients, or contaminants.

These concerns are separate from the question of whether properly manufactured retatrutide may eventually become an effective prescription medication.

The FDA’s Position on Retatrutide and Compounding

This is an especially important point because many patients have become familiar with compounded weight-loss medications.

The FDA recognizes that medications can fall into different regulatory categories.

FDA-approved medications: Drugs such as Wegovy and Zepbound have undergone FDA review for their approved uses, including evidence concerning safety, effectiveness, dosing, and manufacturing quality.

Lawfully compounded medications: Under specific legal conditions, licensed pharmacies or qualified facilities may prepare compounded medications for patients with legitimate medical needs. However, compounded drugs are not FDA-approved, and the FDA does not review each compounded preparation for safety, effectiveness, or quality before marketing.

Investigational medications: Drugs such as retatrutide remain under clinical investigation and have not received FDA approval for routine prescribing.

The FDA explicitly states:

“Retatrutide and cagrilintide cannot be used in compounding under federal law.”

The agency further explains that retatrutide is not an ingredient in an FDA-approved drug and has not been found safe and effective for any condition through the FDA approval process.

In other words, calling a product “compounded retatrutide” or “Peptide” does not make it a legally authorized prescription treatment.

As of October 2026, retatrutide remains investigational.

What If You’ve Already Purchased or Used an Unapproved Product?

First, don’t panic. Using an unverified product does not mean someone will necessarily experience harm.

However, I recommend not taking another dose of an unapproved, unverified product and contacting a qualified healthcare professional promptly—even if you currently feel well.

Tell your clinician what you purchased, where you obtained it, how much you used, when you used it, and whether you’re taking other medications.

Keep the packaging, vial, purchase records, and dosing information available for review.

Seek emergency medical attention for chest pain, fainting, difficulty breathing, a dangerously rapid heartbeat accompanied by weakness or dizziness, confusion, severe or persistent abdominal pain, or repeated vomiting with an inability to keep fluids down.

Severe dehydration can affect blood pressure, kidney function, and electrolyte balance. Persistent gastrointestinal symptoms should not be ignored.

For immediate exposure guidance, contact Poison Control at 1-800-222-1222. Call 911 for life-threatening symptoms.

Patients and healthcare professionals can also report suspected adverse events through the FDA’s MedWatch program.

The goal isn’t to judge someone for trying to improve their weight. It’s to protect their health and help them make informed decisions.

Effective Weight Management Requires More Than an Injection

I understand why newer obesity medications generate excitement.

After more than two decades helping patients manage their weight, I’ve seen how difficult long-term weight management can be—even for highly motivated people.

Appetite regulation, insulin resistance, genetics, sleep, medications, hormonal changes, and the body’s response to weight loss all influence the process.

Modern GLP-1 and GIP-based medications can be valuable treatment tools for appropriately selected patients. But they have limitations, including side effects, variable individual responses, cost, access, and the need for long-term maintenance.

I also don’t want patients focusing exclusively on how quickly the number on the scale decreases.

What happens to your body composition matters.

When someone loses substantial weight, we want to reduce unhealthy body fat while preserving as much muscle, strength, and physical function as possible.

Muscle supports glucose metabolism, mobility, stability, and independence as we age.

That’s why responsible obesity treatment includes appropriate nutrition, sufficient protein, resistance exercise when feasible, metabolic evaluation, medication monitoring, and ongoing follow-up.

At Delight Medical & Wellness Center, we also evaluate how weight management affects blood pressure, blood sugar, cardiovascular risk, energy, and quality of life.

The medication may be an important tool.

But the patient’s long-term health is the strategy.

What This Means for You

If you’re considering a weight-loss medication, don’t make the decision based solely on an online advertisement, social-media testimonial, or promise of dramatic results.

Ask whether the medication is FDA-approved, where it comes from, whether it’s appropriate for your medical history, and how your progress and side effects will be monitored.

If you’re already responding well to an appropriate treatment, you don’t need to abandon your progress because an experimental medication is generating headlines.

Retatrutide may eventually become another valuable option in obesity medicine. Its ongoing research deserves attention and optimism.

But the science behind an investigational medication and the safety of an unauthorized product marketed under its name are not the same thing.

Bottom Line

The recent CBS investigation raises legitimate concerns about the unauthorized market for products advertised as retatrutide.

It does not establish that investigational retatrutide caused the two reported deaths. It also does not mean FDA-approved GLP-1 medications caused these incidents or are broadly unsafe.

What it reinforces is an important principle of medical care:

A promising medication is only part of the equation. Knowing what you’re taking, whether it’s appropriate for you, and how your treatment is monitored matters just as much.

At Delight Medical & Wellness Center, our physician-led approach focuses on individualized evaluation, evidence-based medication selection, body composition, muscle preservation, metabolic health, and sustainable weight management.

Because the goal isn’t to chase the newest injection.

It’s to improve your health—and protect it for years to come.

Physician-Guided Weight Management in Los Angeles

If you’re exploring GLP-1 medications or want a personalized approach to weight and metabolic health, Delight Medical & Wellness Center offers physician-led medical weight management in Los Angeles.

Learn more about our Medical Weight Loss program or call (310) 859-1077 to schedule a consultation.

Dr. Payam Kerendian, DO, founded Delight Medical & Wellness Center in 2005. His clinical focus includes obesity medicine, metabolic health, body composition, and preventive health optimization.